FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study

Summary Introduction Hemophilia is a reality in Cameroon were more than 100 patients are registered and followed‐up in the Yaoundé Hemophilia treatment center. Aim We conducted a cross sectional study in patient living with hemophilia in that setting in order to determine the frequency of Factor VII...

Full description

Saved in:
Bibliographic Details
Published in:International journal of laboratory hematology 2014-10, Vol.36 (5), p.566-570
Main Authors: Balôgôg, P. N., Tagny, C. T., Ndoumba, A., Mbanya, D.
Format: Article
Language:English
Subjects:
Adolescent
Adult
africa
Antibodies - blood
Cameroon
Child
Child, Preschool
Factor IX - administration & dosage
Factor IX - antagonists & inhibitors
Factor VIII - administration & dosage
Factor VIII - antagonists & inhibitors
Female
frequency
Hemophilia
Hemophilia A - blood
Hemophilia A - diagnosis
Hemophilia A - pathology
Hemophilia B - blood
Hemophilia B - diagnosis
Hemophilia B - pathology
Humans
inhibitors
Male
Partial Thromboplastin Time
Severity of Illness Index
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Introduction Hemophilia is a reality in Cameroon were more than 100 patients are registered and followed‐up in the Yaoundé Hemophilia treatment center. Aim We conducted a cross sectional study in patient living with hemophilia in that setting in order to determine the frequency of Factor VIII and IX specific inhibitors and the factors associated their presence. Methods From May to December 2012, venous blood samples of hemophiliac patients undergoing replacement therapy were collected in tubes containing 0.109 m (3.2%) trisodium citrate. Inhibitors were screened by APTT based method using 50 : 50 patients' plasma mixed with normal plasma incubated together for 2 h at 37 °C. Quantitative assay was carried out to measure Bethesda units (BU) with the Bethesda Nijmegen Assay. Samples were labeled as low titer inhibitor when
ISSN:1751-5521
1751-553X
DOI:10.1111/ijlh.12190